JP2005534636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005534636A5 JP2005534636A5 JP2004505373A JP2004505373A JP2005534636A5 JP 2005534636 A5 JP2005534636 A5 JP 2005534636A5 JP 2004505373 A JP2004505373 A JP 2004505373A JP 2004505373 A JP2004505373 A JP 2004505373A JP 2005534636 A5 JP2005534636 A5 JP 2005534636A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- phenyl
- imidazo
- quinolin
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- -1 hydroxy, amino Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 125000000962 organic group Chemical group 0.000 claims description 7
- 210000002307 prostate Anatomy 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 201000008275 breast carcinoma Diseases 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 230000009826 neoplastic cell growth Effects 0.000 claims description 4
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 210000004100 adrenal gland Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 201000001514 prostate carcinoma Diseases 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 210000001215 vagina Anatomy 0.000 claims description 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 150000003839 salts Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000001905 inorganic group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- OJWYDRGMQWQCBO-UHFFFAOYSA-N 1-(2-fluorophenyl)-3h-imidazo[4,5-c]quinolin-2-one Chemical compound FC1=CC=CC=C1N1C(=O)NC2=C1C1=CC=CC=C1N=C2 OJWYDRGMQWQCBO-UHFFFAOYSA-N 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- BGPKBMKIUFZTME-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-(3-nitrophenyl)imidazo[4,5-c]quinolin-2-one Chemical compound [O-][N+](=O)C1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Cl)C=CC4=NC=C32)=O)=C1 BGPKBMKIUFZTME-UHFFFAOYSA-N 0.000 claims 2
- 125000005974 C6-C14 arylcarbonyl group Chemical group 0.000 claims 2
- 241000023320 Luma <angiosperm> Species 0.000 claims 2
- 206010042135 Stomatitis necrotising Diseases 0.000 claims 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 2
- 201000008585 noma Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- ZNBSRKVMSNKUOS-UHFFFAOYSA-N 1-(2-chlorophenyl)-3-(3-chlorophenyl)-8-methylimidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(C=2C(=CC=CC=2)Cl)C=2C3=CC(C)=CC=C3N=CC=2N1C1=CC=CC(Cl)=C1 ZNBSRKVMSNKUOS-UHFFFAOYSA-N 0.000 claims 1
- MWAYMFYZOJXJMU-UHFFFAOYSA-N 1-(2-chlorophenyl)-3-(3-methoxyphenyl)-8-methylimidazo[4,5-c]quinolin-2-one Chemical compound COC1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(C)C=CC4=NC=C32)=O)=C1 MWAYMFYZOJXJMU-UHFFFAOYSA-N 0.000 claims 1
- YZRRSEDFOUEEHB-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-methyl-3-[3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(C=2C(=CC=CC=2)Cl)C=2C3=CC(C)=CC=C3N=CC=2N1C1=CC=CC(C(F)(F)F)=C1 YZRRSEDFOUEEHB-UHFFFAOYSA-N 0.000 claims 1
- KXTRZVLPEHDUCK-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-methyl-3-phenylimidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(C=2C(=CC=CC=2)Cl)C=2C3=CC(C)=CC=C3N=CC=2N1C1=CC=CC=C1 KXTRZVLPEHDUCK-UHFFFAOYSA-N 0.000 claims 1
- UFKSFNKNOCMZHF-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-methyl-3h-imidazo[4,5-c]quinolin-2-one Chemical compound C1=2C3=CC(C)=CC=C3N=CC=2NC(=O)N1C1=CC=CC=C1Cl UFKSFNKNOCMZHF-UHFFFAOYSA-N 0.000 claims 1
- KUGCFLKQWVVXAM-UHFFFAOYSA-N 1-(2-fluorophenyl)-8-methyl-3h-imidazo[4,5-c]quinolin-2-one Chemical compound C1=2C3=CC(C)=CC=C3N=CC=2NC(=O)N1C1=CC=CC=C1F KUGCFLKQWVVXAM-UHFFFAOYSA-N 0.000 claims 1
- PKKCVYOXEOJQJV-UHFFFAOYSA-N 1-cyclohexyl-6-hexoxy-8-methyl-3h-imidazo[4,5-c]quinolin-2-one Chemical compound O=C1NC2=CN=C3C(OCCCCCC)=CC(C)=CC3=C2N1C1CCCCC1 PKKCVYOXEOJQJV-UHFFFAOYSA-N 0.000 claims 1
- MVBDRSJRMTWGDN-UHFFFAOYSA-N 3-(2-aminophenyl)-8-bromo-1-(2-chlorophenyl)imidazo[4,5-c]quinolin-2-one Chemical compound NC1=CC=CC=C1N1C(=O)N(C=2C(=CC=CC=2)Cl)C2=C3C=C(Br)C=CC3=NC=C21 MVBDRSJRMTWGDN-UHFFFAOYSA-N 0.000 claims 1
- CCMQAMMXZMDLIA-UHFFFAOYSA-N 3-(3-aminophenyl)-1-(2-chlorophenyl)-8-methylimidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(C=2C(=CC=CC=2)Cl)C=2C3=CC(C)=CC=C3N=CC=2N1C1=CC=CC(N)=C1 CCMQAMMXZMDLIA-UHFFFAOYSA-N 0.000 claims 1
- YQXJXFWXKVRRIW-UHFFFAOYSA-N 3-(3-aminophenyl)-8-chloro-1-(2-chlorophenyl)imidazo[4,5-c]quinolin-2-one Chemical compound NC1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Cl)C=CC4=NC=C32)=O)=C1 YQXJXFWXKVRRIW-UHFFFAOYSA-N 0.000 claims 1
- FCQGDVVXCCLVCM-UHFFFAOYSA-N 3-butyl-8-chloro-1-(2-chlorophenyl)imidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(CCCC)C2=CN=C3C=CC(Cl)=CC3=C2N1C1=CC=CC=C1Cl FCQGDVVXCCLVCM-UHFFFAOYSA-N 0.000 claims 1
- NAZJWZFPCSAOHR-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-3-(3-chlorophenyl)imidazo[4,5-c]quinolin-2-one Chemical compound ClC1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Br)C=CC4=NC=C32)=O)=C1 NAZJWZFPCSAOHR-UHFFFAOYSA-N 0.000 claims 1
- XXVXFJLNTOEEKR-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-3-(3-methoxyphenyl)imidazo[4,5-c]quinolin-2-one Chemical compound COC1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Br)C=CC4=NC=C32)=O)=C1 XXVXFJLNTOEEKR-UHFFFAOYSA-N 0.000 claims 1
- ZROZVGYZVPABDO-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-3-(3-nitrophenyl)imidazo[4,5-c]quinolin-2-one Chemical compound [O-][N+](=O)C1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Br)C=CC4=NC=C32)=O)=C1 ZROZVGYZVPABDO-UHFFFAOYSA-N 0.000 claims 1
- ICJRYLZOAZRYHV-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-3-[3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound FC(F)(F)C1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Br)C=CC4=NC=C32)=O)=C1 ICJRYLZOAZRYHV-UHFFFAOYSA-N 0.000 claims 1
- PGKNBGGQQHNSRR-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-3-ethylimidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(CC)C2=CN=C3C=CC(Br)=CC3=C2N1C1=CC=CC=C1Cl PGKNBGGQQHNSRR-UHFFFAOYSA-N 0.000 claims 1
- QASHQZJYQGDZOF-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(C)C2=CN=C3C=CC(Br)=CC3=C2N1C1=CC=CC=C1Cl QASHQZJYQGDZOF-UHFFFAOYSA-N 0.000 claims 1
- IONOGCVKZSKRGF-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-3-phenylimidazo[4,5-c]quinolin-2-one Chemical compound ClC1=CC=CC=C1N1C(=O)N(C=2C=CC=CC=2)C2=C1C1=CC(Br)=CC=C1N=C2 IONOGCVKZSKRGF-UHFFFAOYSA-N 0.000 claims 1
- SIQZFWRLJUKKCD-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-3-propan-2-ylimidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(C(C)C)C2=CN=C3C=CC(Br)=CC3=C2N1C1=CC=CC=C1Cl SIQZFWRLJUKKCD-UHFFFAOYSA-N 0.000 claims 1
- HFYDAZHTIXGXLX-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-3h-imidazo[4,5-c]quinolin-2-one Chemical compound ClC1=CC=CC=C1N1C(=O)NC2=C1C1=CC(Br)=CC=C1N=C2 HFYDAZHTIXGXLX-UHFFFAOYSA-N 0.000 claims 1
- DPERJEFFYWQKRO-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-(2,2-dimethylpropyl)imidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(CC(C)(C)C)C2=CN=C3C=CC(Cl)=CC3=C2N1C1=CC=CC=C1Cl DPERJEFFYWQKRO-UHFFFAOYSA-N 0.000 claims 1
- JXSPPLWZSQAOGD-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-(2,3-dihydroxypropyl)imidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(CC(O)CO)C2=CN=C3C=CC(Cl)=CC3=C2N1C1=CC=CC=C1Cl JXSPPLWZSQAOGD-UHFFFAOYSA-N 0.000 claims 1
- IPCMFDPJMZDJEJ-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-(2-methylpropyl)imidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(CC(C)C)C2=CN=C3C=CC(Cl)=CC3=C2N1C1=CC=CC=C1Cl IPCMFDPJMZDJEJ-UHFFFAOYSA-N 0.000 claims 1
- LANHQWYOGQDTCD-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-(3-chlorophenyl)imidazo[4,5-c]quinolin-2-one Chemical compound ClC1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Cl)C=CC4=NC=C32)=O)=C1 LANHQWYOGQDTCD-UHFFFAOYSA-N 0.000 claims 1
- ZWXQULFXEOEXCH-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-(3-methoxyphenyl)imidazo[4,5-c]quinolin-2-one Chemical compound COC1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Cl)C=CC4=NC=C32)=O)=C1 ZWXQULFXEOEXCH-UHFFFAOYSA-N 0.000 claims 1
- ICCYUHZUVRQZAM-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-(cyclohexylmethyl)imidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(C=2C(=CC=CC=2)Cl)C=2C3=CC(Cl)=CC=C3N=CC=2N1CC1CCCCC1 ICCYUHZUVRQZAM-UHFFFAOYSA-N 0.000 claims 1
- RCXLUPVATKGDNS-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-(cyclopropylmethyl)imidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(C=2C(=CC=CC=2)Cl)C=2C3=CC(Cl)=CC=C3N=CC=2N1CC1CC1 RCXLUPVATKGDNS-UHFFFAOYSA-N 0.000 claims 1
- MEASAAQFFXPMHM-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-(furan-3-ylmethyl)imidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(C=2C(=CC=CC=2)Cl)C=2C3=CC(Cl)=CC=C3N=CC=2N1CC=1C=COC=1 MEASAAQFFXPMHM-UHFFFAOYSA-N 0.000 claims 1
- MSEKIAPUFVTREV-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-[3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound FC(F)(F)C1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Cl)C=CC4=NC=C32)=O)=C1 MSEKIAPUFVTREV-UHFFFAOYSA-N 0.000 claims 1
- QDQQGZWEVKSMRQ-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-ethylimidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(CC)C2=CN=C3C=CC(Cl)=CC3=C2N1C1=CC=CC=C1Cl QDQQGZWEVKSMRQ-UHFFFAOYSA-N 0.000 claims 1
- MJAHEPKISOLZNP-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-heptylimidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(CCCCCCC)C2=CN=C3C=CC(Cl)=CC3=C2N1C1=CC=CC=C1Cl MJAHEPKISOLZNP-UHFFFAOYSA-N 0.000 claims 1
- STBRITKMWPCULD-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3-phenylimidazo[4,5-c]quinolin-2-one Chemical compound O=C1N(C=2C(=CC=CC=2)Cl)C=2C3=CC(Cl)=CC=C3N=CC=2N1C1=CC=CC=C1 STBRITKMWPCULD-UHFFFAOYSA-N 0.000 claims 1
- LOLYSJJSHSFQHO-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)-3h-imidazo[4,5-c]quinolin-2-one Chemical compound C1=2C3=CC(Cl)=CC=C3N=CC=2NC(=O)N1C1=CC=CC=C1Cl LOLYSJJSHSFQHO-UHFFFAOYSA-N 0.000 claims 1
- HBRBYVCDBVLLDY-UHFFFAOYSA-N 8-chloro-1-(2-fluorophenyl)-3h-imidazo[4,5-c]quinolin-2-one Chemical compound FC1=CC=CC=C1N1C(=O)NC2=C1C1=CC(Cl)=CC=C1N=C2 HBRBYVCDBVLLDY-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- 241000255925 Diptera Species 0.000 claims 1
- 208000006402 Ductal Carcinoma Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 201000003761 Vaginal carcinoma Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000005179 adrenal carcinoma Diseases 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000010749 gastric carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical compound C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- GINXKRGXHUMJRS-UHFFFAOYSA-N n-[3-[1-(2-chlorophenyl)-8-methyl-2-oxoimidazo[4,5-c]quinolin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(C)C=CC4=NC=C32)=O)=C1 GINXKRGXHUMJRS-UHFFFAOYSA-N 0.000 claims 1
- LGWLXYWKCWPTBU-UHFFFAOYSA-N n-[3-[8-bromo-1-(2-chlorophenyl)-2-oxoimidazo[4,5-c]quinolin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Br)C=CC4=NC=C32)=O)=C1 LGWLXYWKCWPTBU-UHFFFAOYSA-N 0.000 claims 1
- OWXIEPANRNEJEU-UHFFFAOYSA-N n-[3-[8-chloro-1-(2-chlorophenyl)-2-oxoimidazo[4,5-c]quinolin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(N2C(N(C=3C(=CC=CC=3)Cl)C3=C4C=C(Cl)C=CC4=NC=C32)=O)=C1 OWXIEPANRNEJEU-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000020615 rectal carcinoma Diseases 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 102100030011 Endoribonuclease Human genes 0.000 description 3
- 101710199605 Endoribonuclease Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- UTOMICFLROGMAE-UHFFFAOYSA-N quinoline-3,4-diamine Chemical compound C1=CC=CC2=C(N)C(N)=CN=C21 UTOMICFLROGMAE-UHFFFAOYSA-N 0.000 description 3
- QTCIUOKGMTZGMU-UHFFFAOYSA-N 1-(2-bromophenyl)-8-phenylimidazo[4,5-c]quinoline Chemical class BrC1=CC=CC=C1N1C2=C3C=C(C=4C=CC=CC=4)C=CC3=NC=C2N=C1 QTCIUOKGMTZGMU-UHFFFAOYSA-N 0.000 description 2
- CHQRBORBXBUQHD-UHFFFAOYSA-N 2-(4-fluorophenyl)quinoline-3,4-diamine Chemical compound FC1=CC=C(C=C1)C1=NC2=CC=CC=C2C(=C1N)N CHQRBORBXBUQHD-UHFFFAOYSA-N 0.000 description 2
- CSSZKGFNMIFWKQ-UHFFFAOYSA-N 6-fluoro-4-n-(2-fluorophenyl)quinoline-3,4-diamine Chemical compound NC1=CN=C2C=CC(F)=CC2=C1NC1=CC=CC=C1F CSSZKGFNMIFWKQ-UHFFFAOYSA-N 0.000 description 2
- PADWRLXIMSPJJS-UHFFFAOYSA-N 8-chloro-1-phenylimidazo[4,5-c]quinoline Chemical compound C1=2C3=CC(Cl)=CC=C3N=CC=2N=CN1C1=CC=CC=C1 PADWRLXIMSPJJS-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 206010061968 Gastric neoplasm Diseases 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- VHBPTPVXBMZADO-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-ethylimidazo[4,5-c]quinoline Chemical compound C1=2C3=CC(CC)=CC=C3N=CC=2N=CN1C1=CC=CC=C1Cl VHBPTPVXBMZADO-UHFFFAOYSA-N 0.000 description 1
- XKPHJSIJSWEHQY-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-methoxyimidazo[4,5-c]quinoline Chemical compound C1=2C3=CC(OC)=CC=C3N=CC=2N=CN1C1=CC=CC=C1Cl XKPHJSIJSWEHQY-UHFFFAOYSA-N 0.000 description 1
- LWDWBGPVIQOHBG-UHFFFAOYSA-N 1-(4-fluorophenyl)imidazo[4,5-c]quinoline Chemical compound C1=CC(F)=CC=C1N1C2=C3C=CC=CC3=NC=C2N=C1 LWDWBGPVIQOHBG-UHFFFAOYSA-N 0.000 description 1
- IEBLZKGNWVVCIZ-UHFFFAOYSA-N 4-n-(2-chlorophenyl)-6-methoxyquinoline-3,4-diamine Chemical compound C12=CC(OC)=CC=C2N=CC(N)=C1NC1=CC=CC=C1Cl IEBLZKGNWVVCIZ-UHFFFAOYSA-N 0.000 description 1
- FUANNGRBUVCFMW-UHFFFAOYSA-N 5-methoxy-2-(2-nitroethylideneamino)benzoic acid Chemical compound COC1=CC=C(N=CC[N+]([O-])=O)C(C(O)=O)=C1 FUANNGRBUVCFMW-UHFFFAOYSA-N 0.000 description 1
- WWYMTCLDNGUQFF-UHFFFAOYSA-N 6-methoxy-3-nitro-1h-quinolin-4-one Chemical compound N1=CC([N+]([O-])=O)=C(O)C2=CC(OC)=CC=C21 WWYMTCLDNGUQFF-UHFFFAOYSA-N 0.000 description 1
- HCIMPYLFNICPJW-UHFFFAOYSA-N 7-chloro-1-(4-fluorophenyl)imidazo[4,5-c]quinoline Chemical compound C1=CC(F)=CC=C1N1C2=C3C=CC(Cl)=CC3=NC=C2N=C1 HCIMPYLFNICPJW-UHFFFAOYSA-N 0.000 description 1
- HVPHUJZCYZVLPJ-UHFFFAOYSA-N 7-chloro-4-n-(4-fluorophenyl)quinoline-3,4-diamine Chemical compound NC1=CN=C2C=C(Cl)C=CC2=C1NC1=CC=C(F)C=C1 HVPHUJZCYZVLPJ-UHFFFAOYSA-N 0.000 description 1
- DSPDLGSSJPXKIS-UHFFFAOYSA-N 8-chloro-1-(2-chlorophenyl)imidazo[4,5-c]quinoline-4-carbonitrile Chemical compound C1=2C3=CC(Cl)=CC=C3N=C(C#N)C=2N=CN1C1=CC=CC=C1Cl DSPDLGSSJPXKIS-UHFFFAOYSA-N 0.000 description 1
- AAHKIYQVUPHGDC-UHFFFAOYSA-N 8-fluoro-1-(2-fluorophenyl)imidazo[4,5-c]quinoline Chemical compound C1=2C3=CC(F)=CC=C3N=CC=2N=CN1C1=CC=CC=C1F AAHKIYQVUPHGDC-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0211649.9 | 2002-05-21 | ||
| GBGB0211649.9A GB0211649D0 (en) | 2002-05-21 | 2002-05-21 | Organic compounds |
| PCT/EP2003/005291 WO2003097641A2 (en) | 2002-05-21 | 2003-05-20 | 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005534636A JP2005534636A (ja) | 2005-11-17 |
| JP2005534636A5 true JP2005534636A5 (https=) | 2010-05-06 |
| JP4707389B2 JP4707389B2 (ja) | 2011-06-22 |
Family
ID=9937093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505373A Expired - Fee Related JP4707389B2 (ja) | 2002-05-21 | 2003-05-20 | プロテインキナーゼ依存性疾患の処置における１Ｈ−イミダゾ［４，５−ｃ］キノリン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7998972B2 (https=) |
| EP (1) | EP1509521B8 (https=) |
| JP (1) | JP4707389B2 (https=) |
| CN (1) | CN100475207C (https=) |
| AT (1) | ATE405564T1 (https=) |
| AU (1) | AU2003240680A1 (https=) |
| BR (1) | BR0311221A (https=) |
| CA (1) | CA2485012A1 (https=) |
| DE (1) | DE60323090D1 (https=) |
| DK (1) | DK1509521T3 (https=) |
| ES (1) | ES2312783T3 (https=) |
| GB (1) | GB0211649D0 (https=) |
| PT (1) | PT1509521E (https=) |
| SI (1) | SI1509521T1 (https=) |
| WO (1) | WO2003097641A2 (https=) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| HUE025145T2 (en) | 2002-02-22 | 2016-01-28 | Meda Ab | A method for reducing and treating immunosuppression induced by ultraviolet B radiation |
| JP2005538057A (ja) | 2002-06-07 | 2005-12-15 | スリーエム イノベイティブ プロパティズ カンパニー | エーテル置換イミダゾピリジン |
| PT1539752E (pt) * | 2002-07-26 | 2007-05-31 | Teva Gyogyszergyar Zartkoeruen | Preparação de 1h-imidazo [4,5-c] quinolina-4-aminas via novos intermediários imidazo [4,5-c] quinolina-4-ciano e 1h-imidazo [4,5-c] quinolina-4-carboxamida |
| CA2510375A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| WO2004110991A2 (en) | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES |
| CN1852711A (zh) | 2003-08-05 | 2006-10-25 | 3M创新有限公司 | 使用免疫响应调节化合物的传染病预防 |
| BRPI0413558A (pt) | 2003-08-12 | 2006-10-17 | 3M Innovative Properties Co | compostos contendo imidazo substituìdo por hidroxilamina |
| US7799800B2 (en) * | 2003-08-14 | 2010-09-21 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
| US8961477B2 (en) | 2003-08-25 | 2015-02-24 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
| AU2004268625B2 (en) | 2003-08-27 | 2011-03-31 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| AU2004270201A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
| AR046046A1 (es) | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| KR20060120069A (ko) | 2003-10-03 | 2006-11-24 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피라졸로피리딘 및 그의 유사체 |
| EP1685129A4 (en) * | 2003-11-14 | 2008-10-22 | 3M Innovative Properties Co | OXIMSUBSTITUTED IMIDAZORING CONNECTIONS |
| CA2545825A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| CA2547020C (en) | 2003-11-25 | 2014-03-25 | 3M Innovative Properties Company | 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier |
| EP1686992A4 (en) * | 2003-11-25 | 2009-11-04 | 3M Innovative Properties Co | HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME |
| US8940755B2 (en) | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| JP2007513170A (ja) * | 2003-12-04 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | スルホン置換イミダゾ環エーテル |
| JP2007517035A (ja) | 2003-12-29 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン |
| JP2007530450A (ja) * | 2003-12-29 | 2007-11-01 | スリーエム イノベイティブ プロパティズ カンパニー | ピペラジン、［１，４］ジアゼパン、［１，４］ジアゾカン、および［１，５］ジアゾカン縮合イミダゾ環化合物 |
| EP1699788A2 (en) | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
| WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| WO2005123079A2 (en) * | 2004-06-14 | 2005-12-29 | 3M Innovative Properties Company | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| US7884207B2 (en) * | 2004-06-18 | 2011-02-08 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
| EP1789042B1 (en) * | 2004-09-02 | 2012-05-02 | 3M Innovative Properties Company | 1-alkoxy 1h-imidazo ring systems and methods |
| WO2006029115A2 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
| EA200700244A1 (ru) * | 2004-12-27 | 2007-06-29 | Ю Эс Ви ЛИМИТЕД | СПОСОБ ПОЛУЧЕНИЯ 4-АМИНО-1-ИЗОБУТИЛ-1H-ИМИДАЗО-[4,5-c]ХИНОЛИНА (ИМИХИМОД) |
| JP5543068B2 (ja) | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物 |
| EP1831221B1 (en) | 2004-12-30 | 2012-08-08 | 3M Innovative Properties Company | Substituted chiral fused 1,2 imidazo 4,5-c ring compounds |
| CA2592897A1 (en) * | 2004-12-30 | 2006-07-13 | Takeda Pharmaceutical Company Limited | 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate |
| PL1830876T3 (pl) | 2004-12-30 | 2015-09-30 | Meda Ab | Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi |
| US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| JP2008526752A (ja) * | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節剤化合物の多経路投与 |
| AU2006210392A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune response modifiers |
| US8378102B2 (en) | 2005-02-09 | 2013-02-19 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods |
| AU2006212765B2 (en) | 2005-02-09 | 2012-02-02 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
| EP1845988A2 (en) | 2005-02-11 | 2007-10-24 | 3M Innovative Properties Company | Substituted imidazoquinolines and imidazonaphthyridines |
| AU2006213746A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods |
| AU2006216686A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
| JP2008531567A (ja) | 2005-02-23 | 2008-08-14 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ヒドロキシアルキル置換イミダゾキノリン化合物および方法 |
| EP1851220A2 (en) | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazonaphthyridines |
| EP1851224A2 (en) | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
| AU2006232375A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| EP1869043A2 (en) | 2005-04-01 | 2007-12-26 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ITMI20051292A1 (it) * | 2005-07-08 | 2007-01-09 | Dipharma Spa | Procedimento per la purificazione di imiquimod |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| EA200800782A1 (ru) | 2005-09-09 | 2008-08-29 | Коли Фармасьютикал Груп, Инк. | ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ |
| KR20080083270A (ko) | 2005-11-04 | 2008-09-17 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법 |
| CN101287713A (zh) | 2005-11-30 | 2008-10-15 | 三菱化学株式会社 | 有机化合物、电荷传输材料、电荷传输材料用组合物和有机电致发光元件 |
| EP1988896A4 (en) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | CONJUGATES TO MODIFY IMMUNE REACTIONS |
| WO2007103308A2 (en) | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| US8329721B2 (en) | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
| ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| TW200813021A (en) * | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
| US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
| CN101115224B (zh) * | 2006-07-28 | 2010-06-16 | 华为技术有限公司 | 用于ims网络的短信分叉方法及系统 |
| EP2057164A1 (en) | 2006-08-07 | 2009-05-13 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| US8178539B2 (en) | 2006-09-06 | 2012-05-15 | 3M Innovative Properties Company | Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods |
| KR20140091718A (ko) | 2006-11-20 | 2014-07-22 | 노파르티스 아게 | 2-메틸-2-［4-(3-메틸-2-옥소-8-퀴놀린-3-일-2,3-디히드로-이미다조［4,5-ｃ］퀴놀린-1-일)-페닐］-프로피오니트릴의 염 및 결정 형태 |
| RS54510B1 (sr) | 2006-11-22 | 2016-06-30 | Incyte Holdings Corporation | Imidazotriazini i imidazopirimidini kao inhibitori kinaze |
| US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| AU2008218806B2 (en) | 2007-02-20 | 2011-12-01 | Novartis Ag | Imidazoquinolines as dual lipid kinase and mTOR inhibitors |
| KR20100126553A (ko) * | 2008-03-26 | 2010-12-01 | 노파르티스 아게 | Ｖｅｇｆ-유도성 혈관신생 과정의 유력한 조절제로서의 이미다조퀴놀린 및 피리미딘 유도체 |
| TWI472529B (zh) | 2008-05-21 | 2015-02-11 | Incyte Corp | ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法 |
| US8557805B2 (en) | 2008-12-29 | 2013-10-15 | Takeda Pharmaceutical Company Limited | Fused ring compound and use thereof |
| AU2010255727B2 (en) * | 2009-06-04 | 2013-02-28 | Novartis Ag | 1H-imidazo[4,5-c]quinolinone derivatives |
| AU2009349135A1 (en) * | 2009-06-30 | 2012-02-16 | Piramal Enterprises Limited | Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation |
| EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| MX2012008898A (es) | 2010-02-03 | 2012-11-06 | Incyte Corp | Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met. |
| WO2011144622A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | 1h - imidazo [4, 5 - c] quinolines |
| DE102010025786A1 (de) * | 2010-07-01 | 2012-01-05 | Merck Patent Gmbh | Pyrazolochinoline |
| US9242980B2 (en) | 2010-08-17 | 2016-01-26 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
| CN102372711B (zh) * | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| WO2012075253A2 (en) * | 2010-12-03 | 2012-06-07 | Novartis Ag | Pharmaceutical compositions |
| US20130310374A1 (en) * | 2010-12-06 | 2013-11-21 | Piramal Enterprises Limited` | Substituted Imidazoquinoline Derivatives |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| JP6460789B2 (ja) | 2011-06-03 | 2019-01-30 | スリーエム イノベイティブ プロパティズ カンパニー | ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体 |
| BR112013031039B1 (pt) | 2011-06-03 | 2020-04-28 | 3M Innovative Properties Co | compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado |
| WO2013007768A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| US20140309257A1 (en) * | 2011-11-11 | 2014-10-16 | The Regents Of The University Of Colorado, A Body Corporate | Topoisomerase inhibitors and methods of making and use as therapeutic agents |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2014028566A1 (en) * | 2012-08-16 | 2014-02-20 | Novartis Ag | Combination of pi3k inhibitor and c-met inhibitor |
| WO2014177915A1 (en) | 2013-05-01 | 2014-11-06 | Piramal Enterprises Limited | Cancer combination therapy using imidazo[4,5-c]quinoline derivatives |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| WO2015073804A2 (en) * | 2013-11-15 | 2015-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of blocking transmission of malarial parasite |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| NO2714752T3 (https=) * | 2014-05-08 | 2018-04-21 | ||
| AU2015290007B2 (en) * | 2014-07-14 | 2019-11-21 | Advenchen Pharmaceuticals, Nanjing Ltd. | Fused quinoline compunds as pi3k, mTor inhibitors |
| DE102014226656A1 (de) | 2014-12-19 | 2016-06-23 | Robert Bosch Gmbh | Verfahren zum Betreiben eines Abgasnachbehandlungssystems für eine Brennkraftmaschine |
| FR3031105B1 (fr) * | 2014-12-31 | 2018-04-06 | Universite De Montpellier | Nouveaux imidazo[1,2-a]quinoxalines et derives pour le traitement des cancers |
| RS62082B1 (sr) | 2015-04-02 | 2021-08-31 | Merck Patent Gmbh | Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze |
| CN114805352B (zh) | 2015-07-11 | 2023-09-15 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的吡咯并吡啶取代的稠合喹啉化合物 |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| WO2017091757A1 (en) | 2015-11-24 | 2017-06-01 | Portola Pharmaceuticals, Inc. | Isotopically enriched betrixaban |
| CN106496036A (zh) * | 2016-09-29 | 2017-03-15 | 福建天富生物科技发展有限公司 | 一种抗凝血药物中间体5‑甲氧基‑2‑硝基苯甲酸的制备方法 |
| CN110023312A (zh) | 2016-10-13 | 2019-07-16 | 由卫生与公众服务部部长代表的美利坚合众国 | 阻止疟疾寄生虫传播的化合物和方法 |
| WO2019123178A1 (en) | 2017-12-20 | 2019-06-27 | 3M Innovative Properties Company | Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
| CN118619944A (zh) | 2019-06-06 | 2024-09-10 | 北京泰德制药股份有限公司 | 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 |
| CN110606850A (zh) * | 2019-09-11 | 2019-12-24 | 中山大学 | 一种3-苯并[4,5]咪唑[1,2-a]吡嗪-1-胺类化合物及其制备方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1271477A (en) * | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| GB8717644D0 (en) | 1987-07-24 | 1987-09-03 | Smithkline Beckman Intercredit | Compounds |
| EP0385630B1 (en) * | 1989-02-27 | 1996-11-27 | Riker Laboratories, Inc. | 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals |
| CA2011504C (en) | 1989-03-07 | 1998-06-02 | Kenji Ohmori | Imidazoquinolone derivatives |
| US4929624A (en) * | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5037986A (en) * | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
| GB8928281D0 (en) * | 1989-12-14 | 1990-02-21 | Smith Kline French Lab | Compounds |
| DE69229114T2 (de) | 1991-03-01 | 1999-11-04 | Minnesota Mining And Mfg. Co., Saint Paul | 1,2-substituierte 1h-imidazo[4,5-c]chinolin-4-amine |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5268376A (en) * | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| JPH05213754A (ja) * | 1992-02-03 | 1993-08-24 | Kyowa Hakko Kogyo Co Ltd | 抗潰瘍剤 |
| IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US6069149A (en) * | 1997-01-09 | 2000-05-30 | Terumo Kabushiki Kaisha | Amide derivatives and intermediates for the synthesis thereof |
| KR100251522B1 (ko) | 1997-08-13 | 2000-08-01 | 김충섭 | 할로알콕시기를 함유하는 피롤[3,2-c]퀴놀린 유도체 및 약학적으로 허용되는 그의 염 |
| JPH1180156A (ja) * | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
| JP2000119271A (ja) * | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| DE19911039A1 (de) | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US6541485B1 (en) * | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6451810B1 (en) * | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| AU2220801A (en) | 1999-12-22 | 2001-07-03 | Kyorin Pharmaceutical Co. Ltd. | Tricyclic compounds and addition salts thereof |
| CA2399136A1 (en) * | 2000-02-09 | 2001-08-16 | Hideo Kato | 1h-imidazopyridine derivatives |
| BR0112386A (pt) | 2000-06-22 | 2003-06-10 | 3M Innovative Properies Compan | Sistema e métodos para tratar uma superfìcie mucosal |
| UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| EP1455700A4 (en) * | 2001-11-16 | 2007-02-14 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS |
-
2002
- 2002-05-21 GB GBGB0211649.9A patent/GB0211649D0/en not_active Ceased
-
2003
- 2003-05-20 EP EP03730079A patent/EP1509521B8/en not_active Expired - Lifetime
- 2003-05-20 DK DK03730079T patent/DK1509521T3/da active
- 2003-05-20 JP JP2004505373A patent/JP4707389B2/ja not_active Expired - Fee Related
- 2003-05-20 DE DE60323090T patent/DE60323090D1/de not_active Expired - Lifetime
- 2003-05-20 ES ES03730079T patent/ES2312783T3/es not_active Expired - Lifetime
- 2003-05-20 WO PCT/EP2003/005291 patent/WO2003097641A2/en not_active Ceased
- 2003-05-20 US US10/515,126 patent/US7998972B2/en not_active Expired - Fee Related
- 2003-05-20 AT AT03730079T patent/ATE405564T1/de active
- 2003-05-20 CN CNB038117053A patent/CN100475207C/zh not_active Expired - Fee Related
- 2003-05-20 BR BR0311221-7A patent/BR0311221A/pt not_active IP Right Cessation
- 2003-05-20 AU AU2003240680A patent/AU2003240680A1/en not_active Abandoned
- 2003-05-20 CA CA002485012A patent/CA2485012A1/en not_active Abandoned
- 2003-05-20 SI SI200331434T patent/SI1509521T1/sl unknown
- 2003-05-20 PT PT03730079T patent/PT1509521E/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005534636A5 (https=) | ||
| CN113527299B (zh) | 一类含氮稠环类化合物、制备方法和用途 | |
| AU2013371146C1 (en) | 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same | |
| HUE029275T2 (en) | Phthalazinone ketone derivative, method of preparation and therapeutic use | |
| JP7611934B2 (ja) | ピラゾロピリダジノン化合物、その医薬組成物及びその用途 | |
| WO2022206730A1 (zh) | 嘧啶并吡嗪酮化合物及其用途 | |
| KR20200078610A (ko) | 아미노치환 질소함유 축합고리 화합물 및 그의 제조방법과 용도 | |
| CN110357905B (zh) | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 | |
| EA014312B1 (ru) | ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| WO2013062945A1 (en) | Chemical compounds | |
| TW201712009A (zh) | 具抑制細菌葡萄醣醛酸酶活性之吡唑並［４，３－ｃ］喹啉衍生物 | |
| CN108129484B (zh) | 杂芳环衍生物 | |
| WO2008050808A1 (fr) | Dérivé de 2-aminoquinazoline | |
| CN111699188A (zh) | [1,2,4]三唑并[4,3-a]吡嗪-8-酮衍生物 | |
| CN118234727A (zh) | 用于疗法的6H-咪唑并[1,2-a]吡咯并[2,3-e]吡啶衍生物 | |
| JP2001506242A (ja) | ヘリコバクター・ピロリ感染及びそれらと関連する胃十二指腸疾患を処置するための７−（１−アミノメチル−２−オキサ−７−アザ−ビシクロ［３．３．０］オクト−７−イル）−キノロンカルボン酸及びナフチリドンカルボン酸誘導体の使用 | |
| WO2022127869A1 (zh) | 杂环类jak抑制剂 | |
| CN116096720A (zh) | 二氢吡咯并[2,3-d]哒嗪-7-酮衍生物，其制备方法和应用 | |
| JP7143437B2 (ja) | Ｆｍｓ様チロシンキナーゼ阻害剤 | |
| WO2017049711A1 (zh) | 喹啉类衍生物、其药物组合物、制备方法及应用 | |
| CN115536699B (zh) | 一种新型EGFR-TKIs、制备方法、药物组合物及其应用 | |
| CN116583529B (zh) | 阿比特龙衍生物及其制备方法 | |
| CN111039940B (zh) | 一种Aurora A激酶抑制剂、制备方法、药物组合物及其用途 | |
| WO2026086768A1 (zh) | 杂环抑制剂及其制备方法和用途 | |
| TWI783985B (zh) | 類fms酪胺酸激酶抑制劑 |